Pembrolizumab (Keytruda) will be listed on the PBS from 1 November as a first line treatment of patients with advanced non-small cell lung cancer (NSCLC). In a statement manufacturer MSD said the drug will be reimbursed for patients with metaststic (stage IV) NSCLC who have high expression of PD-L1 (>50%). About 1,200 Australians with NSCLC ...
Already a member?
Enter your email to keep reading.